Pharmacologic class (EPC) · 2 drug pages

Interleukin-13 antagonist: adverse event reports filed with FDA

6,985 reports list a drug in this class as a suspect or interacting product, 2022–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

6,985
reports across the class: 0% of all reports; 2,727
reports, 12 months to June 2026: 2,369 in the 12 months before; 14%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

Interleukin-13 antagonist is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 6,985 adverse event reports received by FDA, 0% of the database, from February 2022 to June 2026.

2,727 reports arrived in the 12 months to June 2026, up 15% from 2,369 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 14% of the class's reports are marked serious, 1.3% record death among the outcomes and 4.9% record hospitalisation, as reported.

Across the class the reactions recorded most often are dermatitis atopic (11.7%), drug ineffective (10.3%) and pruritus (9.1%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
AdbryTralokinumab-ldrm	brand	5,384	1,593	15%	Dermatitis atopic
EbglyssLebrikizumab-lbkz	brand	1,601	1,134	10.9%	Injection site pain

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Dermatitis atopic11.7%815
Drug ineffectivethe medicine did not work as expected10.3%722
Pruritusitching9.1%639
Injection site painpain where the injection was given7.5%523
Rashskin rash6.6%462
Eczemaeczema5%352
Erythemaskin redness3.4%238
Injection site erythemaredness where the injection was given3.3%231
Conjunctivitispink eye3.2%226
Dry skindry skin2.8%199
Injection site pruritusitching where the injection was given2.7%191
Injection site swellingswelling where the injection was given2.7%187
Ocular hyperaemiaa red eye2.5%174
Eye pruritus2.4%171
Urticariahives2.3%163
Product use in unapproved indicationused for a purpose not on the label2.1%145
Arthralgiajoint pain2%139
Hypersensitivityan allergic-type reaction1.9%130
Injection site reactiona reaction where the injection was given1.9%130
Dry eyedry eye1.8%126
Eye irritationeye irritation1.8%123
Headachehead pain1.7%121
Vision blurredblurred vision1.7%119
Skin exfoliationpeeling skin1.7%118
Condition aggravatedthe condition being treated got worse1.5%107

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death1.3%90

Life-threatening0.3%20

Hospitalisation (initial or prolonged)4.9%345

Disability0.3%18

Congenital anomaly0%0

Other serious8.6%604

Not serious86%6,004

Patient age

Under 20%2

2 to 110.2%12

12 to 173.7%258

18 to 4425.5%1,781

45 to 6426.8%1,873

65 to 7411.9%830

75 and over8.2%572

Age not given23.7%1,657

Who reported

Physician6.4%444

Pharmacist37.1%2,588

Other health professional13.7%959

Lawyer0%0

Consumer or non-health professional41.5%2,900

Not given1.3%94

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Interleukin-13 antagonist reports

Which drugs are in the Interleukin-13 antagonist class on this site?

Adbry and Ebglyss. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

6,985 reports through June 2026, 2,727 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

dermatitis atopic (11.7%), drug ineffective (10.3%), pruritus (9.1%), injection site pain (7.5%) and rash (6.6%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.